Clinical trial · Observational
Research of the EML4-ALK Gene Expression in the Pleural Effusion or Tumor Tissue From Lung Cancer Patients
NCT01257308CI-TRIAL-00004171unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
We wants to analyse the EML4-ALK mutation rate in the patients who have non-small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer Patients | Lung Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * 20 or more than 20 years of age * The pathological diagnosis confirmed lung cancer * Patients have achieved pleural effusion, or surgical biopsy to obtain tumor tissue specimens * The patient had signed inform consent Exclusion Criteria: * pleural effusion or tumor tissue can not be obtained * the patient is not suitable to join the research according to the judgement by the investigator
References
Publications (0)
Data not yet available
No reference posted for this study.